SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Company Response from INOVIO PHARMACEUTICALS, INC. (INO) (CIK 0001055726) (INO) — Feb 10, 2020

INOVIO PHARMACEUTICALS, INC. (INO) (CIK 0001055726)
Date: Feb. 10, 2020 · CIK: 0001055726 · Accession: 0001193125-20-029793

AI Filing Summary & Sentiment

File numbers found in text: 333-236202

Date
February 10, 2020
Author
Chief Financial
Form
CORRESP
Company
INOVIO PHARMACEUTICALS, INC. (INO) (CIK 0001055726)

Letter

February 10, 2020

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549

Attn: Ada D. Sarmento

RE: Inovio Pharmaceuticals, Inc.

Registration Statement on Form S-3

Filed January 31, 2020

File No. 333-236202

Acceleration Request

Requested Date:

February 13, 2020

Requested Time:

4:00 P.M. Eastern Time

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (the “Registration Statement”) to become effective on February 13, 2020, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable, or at such later time as the Registrant may orally request via telephone call to the staff (the “Staff”) of the Division of Corporation Finance. The Registrant hereby authorizes each of Brian Leaf and Jeffrey Libson of Cooley LLP, counsel to the Registrant, to make such request on its behalf.

Once the Registration Statement has been declared effective, please orally confirm that event with Brian Leaf of Cooley LLP at (703) 456-8053.

Very truly yours,
Inovio Pharmaceuticals, Inc.

Show Raw Text
CORRESP
1
filename1.htm

CORRESP

February 10, 2020

VIA EDGAR

 United States Securities and Exchange Commission

Division of Corporation Finance

 Office of Life Sciences

100 F Street, N.E.

 Washington, D.C. 20549

Attn: Ada D. Sarmento

RE:
 Inovio Pharmaceuticals, Inc.

Registration Statement on Form S-3

Filed January 31, 2020

File No. 333-236202

Acceleration Request

 Requested Date:

February 13, 2020

 Requested  Time:

4:00 P.M. Eastern Time

 Ladies and Gentlemen:

 In
accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to cause the
above-referenced Registration Statement on Form S-3 (the “Registration Statement”) to become effective on February 13, 2020, at 4:00 p.m., Eastern Time, or as soon thereafter as is
practicable, or at such later time as the Registrant may orally request via telephone call to the staff (the “Staff”) of the Division of Corporation Finance. The Registrant hereby authorizes each of Brian Leaf and Jeffrey
Libson of Cooley LLP, counsel to the Registrant, to make such request on its behalf.

 Once the Registration Statement has been declared effective, please
orally confirm that event with Brian Leaf of Cooley LLP at (703) 456-8053.

 Very truly yours,

Inovio Pharmaceuticals, Inc.

/s/ Peter Kies

 Peter Kies

 Chief Financial
Officer

cc:
 Brian Leaf, Cooley LLP

Jeffrey Libson, Cooley LLP